January 2014 | eNews While cytotoxic chemotherapy remains the cornerstone of most cancer treatment, therapeutic approaches are becoming ever more targeted, with the goal... | [more]
Welcome to Dana-Farber/Harvard Cancer CenterDana-Farber/Harvard Cancer Center (DF/HCC) is the largest comprehensive cancer center in the world, bringing together the cancer research efforts of our seven member institutions: Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, and Massachusetts General Hospital.
Funded by a grant from the National Cancer Institute, we have joined these seven renowned Harvard-affiliated medical centers into one collective force dedicated to the fight against cancer. Based in Boston, DF/HCC consists of more than 1,000 researchers with a singular goal -- to find new and innovative ways to combat cancer.
- Seminars in Oncology: "Exploring the Biological and Translational Potential of the Cancer Epigenome" Posted: 03-06-14
- Seminars in Oncology: "The End of the Metastatic Cascade: Control of the Mesenchymal-to-Epithelial Transition by the TgfBETA-Id1 Signaling Axis" Posted: 02-26-14
- Cancer Disparities Research Symposium with Keynote Speaker Derrick J. Beech, MD, FACS Posted: 02-25-14
Latest Cancer News
January 2014 | eNews Nearly all men with early stage prostate cancer are alive five years after diagnosis, but for patients with metastatic prostate cancer, only one third... | [more]
January 2014 | eNews Acute myeloid leukemia (AML) is a blood malignancy characterized by the proliferation of immature white blood cells, with a concurrent deficiency of... | [more]